Ianalumab

Ianalumab is a human monoclonal antibody designed for the treatment of diseases that are mediated by the B cell activating factor (BAFF), such as systemic lupus erythematosus and Sjögren's syndrome. It was developed by Novartis.

Mechanism of action

Ianalumab works by binding to the B cell activating factor (BAFF), a protein that plays a key role in the survival and proliferation of B cells. By blocking BAFF, ianalumab reduces the number of B cells, which are thought to contribute to the development of autoimmune diseases.

Clinical trials

Ianalumab has been tested in several clinical trials. In a phase II trial for systemic lupus erythematosus, ianalumab showed a significant reduction in disease activity compared to placebo. A phase III trial is currently underway.

Side effects

The most common side effects of ianalumab include infections, headache, and nausea. Serious side effects can include severe infections and allergic reactions.

See also

• Monoclonal antibodies
• Systemic lupus erythematosus
• Sjögren's syndrome
• B cell activating factor
• Novartis

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!